Fetal heart block is a condition in which the electrical signals that coordinate heartbeats are partially or completely interrupted at the atrioventricular (AV) node before birth, causing the fetal heart to beat dangerously slowly. The most common cause is an autoimmune process in which specific antibodies from the mother cross the placenta and damage the developing heart’s conduction tissue. While the condition is rare, it can progress rapidly, carry high mortality, and leave survivors needing lifelong cardiac pacing. Understanding the causes, the narrow window for detection, and the evolving treatment landscape matters for any expecting parent facing this diagnosis.
How Maternal Antibodies Cause Most Cases
The majority of fetal heart block cases are autoimmune in origin. They result from anti-Ro/SSA and anti-La/SSB antibodies circulating in the mother’s bloodstream. These antibodies cross the placenta, enter fetal circulation, and bind to proteins in the fetal heart’s conduction system and muscle cells.1PubMed Central. Autoimmune Congenital Heart Block: A Review of Biomarkers and Management of Pregnancy Once attached, they trigger an inflammatory reaction. Over time, that inflammation leads to scarring and calcification of the AV node, which is the relay point where electrical signals pass from the upper to the lower chambers of the heart.2PubMed Central. Congenital heart block: evidence for a pathogenic role of maternal autoantibodies When scarring becomes severe enough, signals can no longer pass through at all, and complete heart block develops.
The process is sometimes described in degrees. First-degree block means signals are delayed but still get through. Second-degree block means some signals are dropped. Third-degree, or complete heart block, means the upper and lower chambers beat independently of each other, typically leaving the ventricles beating far too slowly to sustain normal blood flow. The condition can progress through these stages quickly, sometimes within a week, which is one reason frequent monitoring matters during high-risk pregnancies.3PubMed Central. Effects of maternal anti-Ro/La antibodies on fetal atrioventricular conduction evaluated with echocardiography: a state-of-the-art review
Many Mothers Have No Symptoms
One of the more unsettling facts about autoimmune congenital heart block is that the mother often feels perfectly healthy. Anti-Ro and anti-La antibodies are associated with autoimmune conditions like lupus and Sjögren syndrome, but many women who carry these antibodies have no diagnosed autoimmune disease at the time of pregnancy. In one study that tracked the mothers of affected children, roughly 40 percent of the women had no symptoms at all when the heart block was identified. Among those who did have a diagnosis, lupus and Sjögren syndrome were the most common, with a significant group having a less-defined autoimmune condition.4PubMed. Autoantibody-associated congenital heart block: outcome in mothers and children Other research confirms that most mothers are asymptomatic at delivery and are only identified because of the birth of an affected child.5PubMed Central. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies
This means a woman can carry the antibodies responsible for fetal heart block without knowing it. The practical implication is that antibody testing is typically recommended when there is a family history of neonatal lupus, a prior pregnancy affected by congenital heart block, or when the mother has a known autoimmune condition. Routine screening of all pregnant women for anti-Ro/La antibodies is not standard practice, partly because the overall risk of heart block in antibody-positive pregnancies is low, estimated at roughly 1 to 2 percent for first pregnancies without a prior affected child.
When Structural Heart Disease Is the Cause
Not all fetal heart block is autoimmune. A smaller proportion of cases are caused by structural abnormalities of the heart itself, where the anatomy of the AV node or surrounding tissue develops abnormally. These cases tend to be associated with complex congenital heart defects such as certain types of septal defects or abnormalities in how the heart’s chambers and valves are arranged. The prognosis in structural cases is generally driven more by the severity of the underlying heart defect than by the heart block alone.6PubMed Central. A review of congenital heart block In contrast, autoimmune heart block typically occurs in hearts that are structurally normal, making the conduction system the sole problem. This distinction matters because treatment strategies, expected outcomes, and the likelihood of needing surgery all depend on whether the heart itself is well-formed.
The Vulnerable Window and How Heart Block Is Detected
Autoimmune congenital heart block tends to develop during a specific period of pregnancy. The fetal conduction system becomes susceptible to antibody-mediated damage somewhere between 16 and 24 weeks of gestation, with the highest risk concentrated between 18 and 24 weeks.7ACR Meeting Abstracts. Timeliness of Fetal Echocardiography for Congenital Heart Block Detection in Anti-Ro/La-Positive Pregnancies Best-practice guidelines recommend that women known to carry anti-Ro or anti-La antibodies start serial fetal echocardiography at 16 to 18 weeks so that any early changes in heart rhythm can be caught before they become irreversible.
Fetal echocardiography is the primary diagnostic tool. Because you cannot attach electrodes to a fetus, clinicians rely on ultrasound to assess how the heart is conducting electricity. One widely used technique involves placing a Doppler probe to simultaneously capture the timing of blood flow through the mitral valve (representing atrial contraction) and through the aortic outflow (representing ventricular contraction). The time gap between these two events serves as a stand-in for the PR interval on an adult electrocardiogram. A prolonged interval suggests first-degree block, and this technique can identify early, potentially reversible conduction abnormalities in at-risk fetuses.8Fetal Diagnosis and Therapy. The Fetal Doppler Mechanical PR Interval: A Validation Study
A newer technology, fetal magnetocardiography, records the tiny magnetic fields generated by the fetal heart’s electrical activity. Unlike ultrasound, it can produce something closer to a true electrical tracing. Though not yet widely available, it has begun to contribute to more precise diagnosis and risk assessment in cases where echocardiography alone leaves uncertainty.9PubMed Central. Contribution of Fetal Magnetocardiography to Diagnosis, Risk Assessment, and Treatment of Fetal Arrhythmia
Treatment During Pregnancy
Once heart block is detected in a fetus, the treatment options depend on how far the condition has progressed. For incomplete block, where some conduction remains, the goal is to halt progression and, if possible, reverse it. For complete block, the realistic goal shifts toward managing complications until the baby can be delivered safely.
Fluorinated glucocorticoids, particularly dexamethasone and betamethasone, are the most commonly used in-utero medications. These steroids cross the placenta efficiently and can reduce the inflammatory response driving the damage to the conduction system. Evidence suggests that complete heart block can sometimes respond to this therapy, with improved cardiac conduction and resolution of associated fluid buildup (hydrops) when inflammation of the heart muscle is part of the picture.10PubMed. Successful in utero therapy of fetal heart block However, fluorinated steroids come with real downsides for both mother and fetus, including effects on fetal growth and adrenal function, maternal glucose control problems, and risk of infection. Their use remains a carefully weighed decision rather than a routine prescription.11PubMed Central. Prevention and treatment in utero of autoimmune-associated congenital heart block
Researchers have also explored intravenous immunoglobulin (IVIG) as a preventive strategy, with the idea that it could lower the mother’s antibody levels or dampen the fetal inflammatory response. A multicenter clinical trial evaluated this approach for mothers whose previous pregnancies were affected by congenital heart block.12PubMed Central. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block IVIG has not become a standard preventive therapy, partly because results were mixed and the treatment is expensive and time-consuming.
Hydroxychloroquine for Prevention
The most promising preventive development in recent years has been hydroxychloroquine, better known by its brand name Plaquenil and widely used for lupus and rheumatoid arthritis. The drug appears to interfere with the process by which maternal antibodies damage fetal heart tissue, and it has been studied specifically in mothers who already lost a previous pregnancy to congenital heart block or neonatal lupus with cardiac involvement.
A prospective clinical trial found that the recurrence rate of congenital heart block in anti-Ro-positive mothers taking hydroxychloroquine was about 7 percent, a reduction of more than half compared to historical recurrence rates, which tend to run around 16 to 18 percent.13PubMed Central. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers A separate multinational analysis corroborated this, showing a recurrence rate of about 7.5 percent in mothers who took hydroxychloroquine versus roughly 21 percent in those who did not. After adjusting for factors like ethnicity and anti-La antibody status, the drug was associated with a roughly fourfold reduction in the odds of recurrence.14PubMed Central. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus
These findings have shifted clinical practice. Hydroxychloroquine is now often recommended for secondary prevention in mothers with a previously affected pregnancy, and some clinicians are considering it for primary prevention in antibody-positive women who have never had an affected child, though the evidence base for that broader use is still growing.
What Happens When the Fetal Heart Fails
The gravest immediate complication of fetal heart block is hydrops fetalis, a condition in which fluid accumulates in the fetal body cavities and soft tissues because the heart is pumping too weakly to maintain normal circulation. Hydrops in the setting of complete heart block is a medical emergency with high mortality. One case report documented non-immune hydrops caused by the cardiac failure that accompanies severe bradycardia, confirmed on echocardiography by significant backflow through the tricuspid valve.15PubMed Central. Fetal bradyarrhythmia causing hydrops fetalis: A journey from fetal echo to autopsy
Attempts at fetal pacing, essentially implanting a temporary pacemaker wire through the uterine wall, have been reported but remain experimental. One early attempt involved placing a ventricular pacing lead in a hydropic fetus with complete AV block caused by maternal autoimmune disease. Although the fetus did not survive, the rationale was that pacing could improve cardiac output enough to reverse the fluid buildup and allow further in-utero development. Researchers noted that earlier intervention, before hydrops becomes severe, could theoretically improve outcomes.16Journal of the American College of Cardiology. Fetal ventricular pacing for hydrops secondary to complete atrioventricular block Work has continued on developing specialized leads for in-utero pacing, though the procedure remains far from routine.17PubMed. New lead for in utero pacing for fetal congenital heart block
Delivery Planning and Neonatal Stabilization
When a fetus with known complete heart block reaches viability, delivery planning becomes crucial. The key is delivering at a center equipped for immediate cardiac pacing if the baby’s heart rate cannot sustain adequate blood flow after birth. Evidence shows that neonates with complete heart block and structurally normal hearts who are monitored before birth and delivered in a planned fashion at a center capable of early pacing can have favorable outcomes.18PubMed. Outcome of high-risk neonates with congenital complete heart block paced in the first 24 hours after birth
For the most critically unstable newborns, particularly preterm infants with limited cardiac reserve, a stepwise approach may be needed. A recent case report described delivery-room transcutaneous pacing (using external pads to stimulate the heart through the chest wall) followed by extracorporeal membrane oxygenation (ECMO) support in the neonatal ICU, buying time until a permanent pacemaker could be placed safely.19PubMed. Delivery-room transcutaneous pacing and ECMO support in the NICU for a preterm neonate with congenital complete heart block These heroic measures underscore why prenatal diagnosis is so valuable: it allows the delivery team to have the right specialists and equipment standing by.
Life After Pacemaker Implantation
For children with isolated (structurally normal heart) congenital complete heart block, pacemaker implantation generally leads to excellent early survival. Most early deaths in this population result from delayed initiation of pacing or from the hemodynamic problems of co-existing congenital heart defects rather than from pacing failure.20Journal of the American College of Cardiology. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela But the long-term story is more complex than “pacemaker in, problem solved.”
A significant proportion of these patients, roughly one in five in one long-term follow-up study, go on to develop dilated cardiomyopathy, a weakening and enlargement of the heart’s pumping chamber. This is likely driven by pacing-induced cardiomyopathy: because the pacemaker stimulates the ventricle from one fixed point rather than activating it through its natural wiring, the heart’s contraction pattern becomes uncoordinated over years and decades of pacing. In that study, the average time between initial pacemaker placement and the need for an upgrade to cardiac resynchronization therapy was over 16 years.21PubMed Central. Long term clinical outcomes in patients requiring cardiac pacing due to congenital complete heart block
Where the pacing lead is placed also appears to matter. A study of children with congenital heart block followed for a median of over 12 years found that pacing from the right ventricular free wall carried a dramatically higher risk of left ventricular dysfunction compared with pacing from the apex of either ventricle. Patients who developed dysfunction and then had their leads relocated or were upgraded to resynchronization therapy showed substantial recovery, with median ejection fraction improving from about 24 percent to nearly 63 percent.22PubMed. Long-term Follow-up of Epicardial Pacing and Left Ventricular Dysfunction in Children With Congenital Heart Block These findings have practical implications for the initial surgical decision about lead placement and argue for ongoing monitoring of heart function, not just rhythm, well into adulthood.
Genetic Susceptibility in the Fetus
Not every fetus exposed to anti-Ro/La antibodies develops heart block. The autoimmune mechanism is considered multifactorial: the antibodies are necessary but not sufficient on their own.23PubMed Central. Atrioventricular block during fetal life Something about the individual fetus’s biology determines whether the antibodies will trigger the cascade of inflammation, fibrosis, and calcification.
One piece of that puzzle appears to be the fetus’s own immune genetics. A family-based study found that certain HLA types, the genes that shape how the immune system recognizes foreign molecules, were associated with heart block risk. The HLA-DRB1*04 allele was significantly more often passed to children who developed congenital heart block, suggesting it makes the fetal heart tissue more vulnerable to antibody-mediated injury. Interestingly, other alleles like HLA-DR*13 showed the opposite pattern, appearing to be transmitted less often to affected children, hinting at a possible protective effect.24Annals of the Rheumatic Diseases. Gene regulation and signaling HLA-DRB1*04 is a novel fetal susceptibility allele in congenital heart block This helps explain why the risk per antibody-positive pregnancy is low and why two siblings exposed to the same maternal antibodies can have very different outcomes.
The Cost Question Around Screening
For mothers known to carry anti-Ro or anti-La antibodies, there is a real question about how intensively to monitor the pregnancy. Screening strategies range from limited surveillance to weekly fetal echocardiography throughout the vulnerable period. A cost-effectiveness analysis compared three approaches: limited screening, targeted screening, and intensive weekly screening. The targeted approach, which concentrates echocardiograms during the highest-risk gestational window, was cost-effective, with an average cost of about $11,000 per pregnancy. Intensive weekly screening nearly doubled the cost to over $23,000 without proportionate gains in outcome, landing it in cost-ineffective territory.25PubMed. Prenatal heart block screening in mothers with SSA/SSB autoantibodies: Targeted screening protocol is a cost-effective strategy These numbers matter because most antibody-positive pregnancies will not result in heart block, and the repeated specialized ultrasounds are a real burden in time, anxiety, and expense. A targeted strategy that focuses monitoring during the weeks of peak vulnerability strikes the best balance between catching early-stage block and avoiding unnecessary testing.